<DOC>
	<DOCNO>NCT00249236</DOCNO>
	<brief_summary>The purpose study assess effectiveness safety risperidone ( antipsychotic medication ) versus placebo treat mania 3 week treatment patient Bipolar I Disorder suffer manic mixed episode .</brief_summary>
	<brief_title>A Study Effectiveness Safety Risperidone Versus Placebo Treatment Manic Mixed Episodes Associated With Bipolar I Disorder</brief_title>
	<detailed_description>Antipsychotic agent , long time , use alleviate severe behavioral problem associate manic episode . Risperidone , widely use treatment schizophrenia , show effective treatment manic mixed episode associate bipolar disorder . This randomized , double-blind study evaluate effectiveness safety risperidone compare placebo treatment patient bipolar disorder experience manic mixed episode . Patients voluntarily hospitalize time study enrollment ( treatment manic episode ) receive study medication take orally , day . Patients receive placebo risperidone start dose 3 mg , gradual dose increase decrease investigator 's discretion within daily dose range 1 6 mg achieve optimal effectiveness , minimize intolerance drug . Treatment risperidone placebo tablet continue 3 week . The primary measure efficacy change baseline end treatment Young Mania Rating Scale ( YMRS ) ; Other efficacy assessment include change : Clinical Global Impression-Severity Illness ( CGI-S ) scale ; Global Assessment Scale ( GAS ) , assess patient 's level functioning ; Positive Negative Syndromes Scale ( PANSS ) , scale measure psychotic symptom . Safety assessment include incidence adverse event throughout study ; measurement vital sign ( temperature , pulse , blood pressure ) evaluation presence severity extrapyramidal symptom Extrapyramidal Symptom Rating Scale ( ESRS ) specify interval ; clinical laboratory test ( hematology , biochemistry , urinalysis ) start end study . The study hypothesis daily treatment risperidone effective placebo , measure Young Mania Rating Scale score , treatment manic phase Bipolar I Disorder . Risperidone oral tablet , 1 mg , take daily evening ; dose 3 mg Day 1 ; dose range 2 - 4 mg Day 2 ; dose range 1 - 5 mg Day 3 ; dose range 1 - 6 mg Days 4 - 21 . Doses may increase decreased investigator 's discretion .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Meets DSMIV criterion Bipolar I Disorder , Most Recent Episode Manic Mixed hospitalize voluntarily study initiation treatment manic episode history ( prior study initiation ) least one document manic mixed episode require treatment total score &gt; =20 Young Mania Rating Scale ( YMRS ) start study Meets DSMIV criterion Schizoaffective Disorder rapid cycling borderline antisocial personality disorder history substance dependence ( exclude nicotine caffeine ) within 3 month prior study initiation seizure disorder female pregnant nursing , lack adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>risperidone</keyword>
	<keyword>antipsychotic agent</keyword>
	<keyword>bipolar disorder</keyword>
	<keyword>manic episode</keyword>
</DOC>